Search research articles
Contact Us
Filters
Showing results (1-10 of 40) with videos related to
Page
of 4
Sort By:
The American Journal of Psychiatry
|
September 1, 2025
Does Xanomeline/Trospium Have Unique Benefits for Cognitive Impairment Associated With Schizophrenia? Response to Tandon
William P Horan, Philip D Harvey, Stephen K Brannan
Journal of Psychiatric Research
|
October 26, 2021
Site-independent confirmation of primary site-based PANSS ratings in a schizophrenia trial
Steven D Targum, Christopher Murphy, Alan Breier, et al.
Psychopharmacology
|
April 10, 2023
Evidence of trospium's ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results
Alan Breier, Stephen K Brannan, Steven M Paul, et al.
Frontiers in Psychiatry
|
November 1, 2024
The potential of muscarinic M<sub>1</sub> and M<sub>4</sub> receptor activators for the treatment of cognitive impairment associated with schizophrenia
Samantha E Yohn, Phillip D Harvey, Stephen K Brannan, et al.
Lancet (London, England)
|
August 10, 2024
Gaining trust through transparency: the EMERGENT-2 trial - Authors' reply
Inder Kaul, Alan Breier, Andrew C Miller, et al.
Translational Psychiatry
|
February 7, 2025
Methods to address functional unblinding of raters in CNS trials
Steven D Targum, William P Horan, Vicki G Davis, et al.
Biological Psychiatry
|
March 27, 2024
Muscarinic Receptor Activators as Novel Treatments for Schizophrenia
Steven M Paul, Samantha E Yohn, Stephen K Brannan, et al.
The International Journal of Neuropsychopharmacology
|
May 10, 2001
Reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine
Martin A. Javors, John P. Houston, Janet L. Tekell, et al.
Schizophrenia (Heidelberg, Germany)
|
December 3, 2022
Safety and tolerability of KarXT (xanomeline-trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia
Christoph U Correll, Angel S Angelov, Andrew C Miller, et al.
Journal of Psychiatric Research
|
December 14, 2004
Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies
Stephen K Brannan, Craig H Mallinckrodt, Michael J Detke, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 40) with videos related to
Sort By:
Page
of 4
The American Journal of Psychiatry
|
September 1, 2025
Does Xanomeline/Trospium Have Unique Benefits for Cognitive Impairment Associated With Schizophrenia? Response to Tandon
William P Horan, Philip D Harvey, Stephen K Brannan
Journal of Psychiatric Research
|
October 26, 2021
Site-independent confirmation of primary site-based PANSS ratings in a schizophrenia trial
Steven D Targum, Christopher Murphy, Alan Breier, et al.
Psychopharmacology
|
April 10, 2023
Evidence of trospium's ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results
Alan Breier, Stephen K Brannan, Steven M Paul, et al.
Frontiers in Psychiatry
|
November 1, 2024
The potential of muscarinic M<sub>1</sub> and M<sub>4</sub> receptor activators for the treatment of cognitive impairment associated with schizophrenia
Samantha E Yohn, Phillip D Harvey, Stephen K Brannan, et al.
Lancet (London, England)
|
August 10, 2024
Gaining trust through transparency: the EMERGENT-2 trial - Authors' reply
Inder Kaul, Alan Breier, Andrew C Miller, et al.
Translational Psychiatry
|
February 7, 2025
Methods to address functional unblinding of raters in CNS trials
Steven D Targum, William P Horan, Vicki G Davis, et al.
Biological Psychiatry
|
March 27, 2024
Muscarinic Receptor Activators as Novel Treatments for Schizophrenia
Steven M Paul, Samantha E Yohn, Stephen K Brannan, et al.
The International Journal of Neuropsychopharmacology
|
May 10, 2001
Reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine
Martin A. Javors, John P. Houston, Janet L. Tekell, et al.
Schizophrenia (Heidelberg, Germany)
|
December 3, 2022
Safety and tolerability of KarXT (xanomeline-trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia
Christoph U Correll, Angel S Angelov, Andrew C Miller, et al.
Journal of Psychiatric Research
|
December 14, 2004
Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies
Stephen K Brannan, Craig H Mallinckrodt, Michael J Detke, et al.
Page
of 4